Ayman Megahed
Doha, DA, Qatar
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Painful diabetic neuropathy is associated with increased nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control.
Journal: Journal of diabetes investigation
Published: December 26, 2020
Insulin resistance limits corneal nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control.
Journal: Journal of diabetes investigation
Published: November 14, 2020
Combination therapy with pioglitazone/exenatide improves beta-cell function and produces superior glycaemic control compared with basal/bolus insulin in poorly controlled type 2 diabetes: A 3-year follow-up of the Qatar study.
Journal: Diabetes, obesity & metabolism
Published: June 01, 2020
Effect of treatment with exenatide and pioglitazone or basal-bolus insulin on diabetic neuropathy: a substudy of the Qatar Study.
Journal: BMJ open diabetes research & care
Published: March 29, 2020
Pioglitazone prevents the increase in plasma ketone concentration associated with dapagliflozin in insulin-treated T2DM patients: Results from the Qatar Study.
Journal: Diabetes, obesity & metabolism
Published: June 18, 2018
Insulin secretion predicts the response to therapy with exenatide plus pioglitazone, but not to basal/bolus insulin in poorly controlled T2DM patients: Results from the Qatar study.
Journal: Diabetes, obesity & metabolism
Published: October 05, 2017
Efficacy of Exenatide Plus Pioglitazone Vs Basal/Bolus Insulin in T2DM Patients With Very High HbA1c.
Journal: The Journal of clinical endocrinology and metabolism
Published: October 10, 2016
Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study.
Journal: Diabetes care
Published: August 11, 2016
Showing 1-9 of 9
Last Updated: 09/26/2026